GLO1 and obesity due to melanocortin 4 receptor deficiency: Pyridoxamine inhibits HFD-induced weight gain and macrophage M1 polarization in obese rats and increases GLO1 expression in perivascular and visceral adipose tissue through the RAGE pathway, where it was speculated that pyridoxamine is a candidate for treating obesity or obesity-related inflammatory complications [107].